Search

Background: Transplant glomerulopathy (TG) is an important cause of late graft loss. The role of angiotensin type 1-receptor antibodies (AT 1 R-Ab) in TG is not known., Methods: All the TG cases (N = 137) between January 2007 and December 2014 (N = 1410) were analyzed. Donor-specific anti-HLA antibodies (DSA) at the time of biopsy and AT 1 R-Ab IgG (positive, >17 UI/mL; "at risk," 10-17 UI/mL; negative, <10 UI/mL) in pre-transplant sera (PT-Ab) and at biopsy time (BT-Ab) were studied., Results: AT 1 R-PT-Ab + and AT 1 R-BT-Ab + patients were 16.5% (51.5% "at risk") and 11.5% (27.4% "at risk"), respectively. Clinical correlations were found between AT 1 R-Ab and HCV infection, number of transplants, and age. Considering Banff scores, ptc was higher in DSA + patients vs AT 1 R-PT-Ab + (P = 0.002) or AT 1 R-BT-Ab + (P = 0.001) without differences in g and chronicity score (ci + ct); cg showed lower scores in DSA + patients vs AT 1 R-BT-Ab + (P = 0.001). Graft survival was not influenced by the presence of AT 1 R-Ab, AT1-R-Ab titer or MFI, but we observed a longer graft survival in patients with both AT 1 R-BT-Ab + or "at risk" and DSA + vs patients positive only for DSA (P = 0.02), for AT 1 R-BT-Ab (P = 0.019) or AT 1 R-BT-Ab "at risk" (P = 0.039)., Conclusion: AT 1 R-Ab showed no independent prognostic role in TG in this pilot analysis., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)